AR041086A1 - Vacuna - Google Patents
VacunaInfo
- Publication number
- AR041086A1 AR041086A1 ARP030103127A ARP030103127A AR041086A1 AR 041086 A1 AR041086 A1 AR 041086A1 AR P030103127 A ARP030103127 A AR P030103127A AR P030103127 A ARP030103127 A AR P030103127A AR 041086 A1 AR041086 A1 AR 041086A1
- Authority
- AR
- Argentina
- Prior art keywords
- immunogens
- refers
- neutralization
- present
- atopic
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 238000006386 neutralization reaction Methods 0.000 abstract 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 abstract 1
- 208000012657 Atopic disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 108010041986 DNA Vaccines Proteins 0.000 abstract 1
- 229940021995 DNA vaccine Drugs 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se refiere a inmunógenos aislados y su uso en el tratamiento de enfermedades que se pueden tratar con neutralización de IL-13, tal como COPD, asma y trastornos atópicos tal como fiebre de heno, alergias de contacto y dermatitis atópica. En particular se refiere a la neutralización de los efectos biológicos de IL-13 mediante la inducción de una respuesta inmune contra la IL-13 mediante la vacunación de un mamífero con inmunógenos que comprenden la frecuencia de aminoácidos mutada o nativa de IL-13, y epítopos auxiliares de células T extranos bien insertados o unidos a la secuencia de IL-13 o presentes en polipéptidos vehículos- La presente también proporciona vacunas de DNA que comprenden una secuencia de polinucleótidos que codifica los inmunógenos de la presente. Se refiere adicionalmente a composiciones farmacéuticas que comprenden dichos inmunógenos y su uso en medicina y a procedimientos para su producción.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0220212A GB0220212D0 (en) | 2002-08-30 | 2002-08-30 | Vaccine |
| GB0304672A GB0304672D0 (en) | 2003-02-28 | 2003-02-28 | Vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041086A1 true AR041086A1 (es) | 2005-04-27 |
Family
ID=31980003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103127A AR041086A1 (es) | 2002-08-30 | 2003-08-28 | Vacuna |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060147417A1 (es) |
| EP (1) | EP1532172A2 (es) |
| JP (1) | JP2006503017A (es) |
| AR (1) | AR041086A1 (es) |
| AU (1) | AU2003259358A1 (es) |
| CA (1) | CA2496409A1 (es) |
| TW (1) | TW200407162A (es) |
| WO (1) | WO2004019974A2 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006503018A (ja) * | 2002-08-30 | 2006-01-26 | グラクソ グループ リミテッド | ワクチン |
| HUE064610T2 (hu) | 2003-12-23 | 2024-04-28 | Genentech Inc | Új anti-IL 13 antitestek és alkalmazásaik |
| DE102004003572A1 (de) * | 2004-01-23 | 2005-08-18 | Bavarian Nordic A/S | Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens |
| KR100639397B1 (ko) * | 2004-03-18 | 2006-10-26 | (주)에스제이바이오메드 | 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물 |
| WO2006055638A2 (en) | 2004-11-17 | 2006-05-26 | Abgenix, Inc. | Fully human monoclonal antibodies to il-13 |
| GB0615881D0 (en) * | 2006-08-10 | 2006-09-20 | Univ Southampton | Novel peptide for treatment of asthma |
| US20110002955A1 (en) * | 2006-09-25 | 2011-01-06 | Sj Biomed Inc. | Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same |
| AU2010269120B2 (en) * | 2009-07-06 | 2015-09-24 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
| US20160166637A1 (en) * | 2013-08-02 | 2016-06-16 | Virginia Tech Intellectual Properties, Inc. | Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction |
| WO2015038884A2 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
| KR102571391B1 (ko) | 2013-09-13 | 2023-08-29 | 제넨테크, 인크. | 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물 |
| WO2019061297A1 (zh) * | 2017-09-29 | 2019-04-04 | 苏州工业园区唯可达生物科技有限公司 | 一种cd4辅助性t细胞表位融合肽及其疫苗 |
| EP3574915A1 (en) | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
| WO2023021195A1 (en) * | 2021-08-20 | 2023-02-23 | Neovacs | mRNA VACCINES COMPRISING IL-4 AND/OR IL-13 RNA AND USES THEREOF |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| US6296843B1 (en) * | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
| CN1355846A (zh) * | 1999-04-23 | 2002-06-26 | 法麦克萨有限公司 | 用于下调节白细胞介素5活性的方法 |
| CA2404763A1 (en) * | 1999-11-11 | 2001-05-17 | Raj K. Puri | Mutated il-13 molecules and their uses |
| US6846486B1 (en) * | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| GB0105360D0 (en) * | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
-
2003
- 2003-08-28 TW TW092123745A patent/TW200407162A/zh unknown
- 2003-08-28 AU AU2003259358A patent/AU2003259358A1/en not_active Abandoned
- 2003-08-28 EP EP03791019A patent/EP1532172A2/en not_active Withdrawn
- 2003-08-28 AR ARP030103127A patent/AR041086A1/es not_active Application Discontinuation
- 2003-08-28 WO PCT/GB2003/003703 patent/WO2004019974A2/en active Application Filing
- 2003-08-28 JP JP2004532284A patent/JP2006503017A/ja active Pending
- 2003-08-28 CA CA002496409A patent/CA2496409A1/en not_active Abandoned
- 2003-08-28 US US10/526,060 patent/US20060147417A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004019974A2 (en) | 2004-03-11 |
| US20060147417A1 (en) | 2006-07-06 |
| AU2003259358A1 (en) | 2004-03-19 |
| EP1532172A2 (en) | 2005-05-25 |
| CA2496409A1 (en) | 2004-03-11 |
| WO2004019974A3 (en) | 2004-07-22 |
| JP2006503017A (ja) | 2006-01-26 |
| AU2003259358A8 (en) | 2004-03-19 |
| TW200407162A (en) | 2004-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041086A1 (es) | Vacuna | |
| AR079114A1 (es) | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas | |
| CY1107973T1 (el) | Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων | |
| WO2011163628A3 (en) | Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof | |
| ES2662801T3 (es) | Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas | |
| WO2015149944A3 (en) | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| AR047392A1 (es) | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines | |
| MX355074B (es) | Inmunoterapia novedosa contra varios tumores incluidos el cancer gastrico y gastrointestinal. | |
| NZ616304A (en) | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses | |
| CO6612199A2 (es) | Pèptidos tau antigènicos y usos de los mismos | |
| TW200806316A (en) | Yeast-based vaccine for inducing an immune response | |
| EA201270713A1 (ru) | Белки на основе фибронектина с каркасными доменами, которые связывают ил-23 | |
| AR081809A1 (es) | Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas | |
| AR061930A1 (es) | Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos | |
| BR112015005987A2 (pt) | vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína | |
| WO2009117116A3 (en) | Heat shock protein gp96 vaccination and methods of using same | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| DE602004028029D1 (en) | Rwendung | |
| ATE473756T1 (de) | Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs | |
| WO2019098759A3 (ko) | 형질전환된 인간세포 및 이의 용도 | |
| ATE520708T1 (de) | Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung | |
| WO2018102774A8 (en) | Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a | |
| WO2005100390A3 (en) | Bob-1 specific t cells and methods to use | |
| WO2012026820A3 (en) | Immunotherapeutic method for treating prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |